<DOC>
	<DOCNO>NCT02715843</DOCNO>
	<brief_summary>This active treatment , extend access study open solely subject successfully complete Core Repeat Dosing portion MT-3724_NHL_001_US clinical study , investigator 's judgment , ( ) progressive disease MT-3724 treatment ( i.e . ; show complete partial response stable disease ) , ( ii ) experience clinical laboratory toxicity would contraindicate MT-3724 dosing ( iii ) acceptable well alternative treatment available .</brief_summary>
	<brief_title>Extended Treatment Access Study MT-3724 Subjects With Relapsed Non-Hodgkin 's B-Cell Lymphoma</brief_title>
	<detailed_description>Each treatment cycle consist 6 dos MT-3724 administer 12 day follow least 9 day observation longer interval dose cycle allow investigator 's discretion ( e.g. , 6 dos MT-2734 12 day follow 16 day observation ) . Subjects extension study may continue receive 6 additional cycle absence clear disease progression toxicity . If subject achieve complete remission , two additional cycle attempt , dose may suspend prior completion maximum 6 cycle . In accordance CFR Title 21 , Part 312.315 , Subpart I ( Expanded Access Investigational Drugs Treatment Use Intermediate-size Populations ) study submit MT-2724 IND ( # 121918 ) FDA review approval . Prior enrol subject study investigator elect participate study responsible ( ) obtain local institutional review board ( IRB ) approval study associate informed consent form , ( ii ) review potential study candidate 's eligibility sponsor ( iii ) obtain potential subject 's sign , local IRB approve informed consent form study prior perform study related activity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Eligible subject must adequately inform study procedure fully consent participation demonstrate signing Informed Consent Form ( ICF ) . Eligible subject must require treatment NHL : tolerate MT3724 throughout MT3724_NHL_001_US Phase I/Ib study ( Core Repeat Dosing ) , successfully complete Core Repeat Dosing portion MT3724_NHL_001_US Phase I/Ib study define protocol , receive treatment NHL since enrollment MT3724_NHL_001_US Phase I/Ib study , maintain stable disease well throughout study assess investigator acceptable well treatment option available . The investigator must document potential subject 's medical record approve treatment option available and/or appropriate potential subject potential subject decline approved treatment option available . Potential subject must continue meet diagnostic criterion BCell NHL allow eligible MT3724_NHL_001_US Phase I/Ib study . Potential subject must receive approved therapy know provide clinical benefit disease subtype eligible must refuse treatment option prior consideration continue compassionate use treatment MT3724 enrollment protocol . In case subject lymphomas highdose chemotherapy autologous stem cell transplantation ( HDASCT ) consider standard curative therapy , eligibility MT3724 compassionate use require subject 's disease relapse HDASCT , subject eligible HD ASCT , subject refuse HDASCT . Potential subject know central nervous system ( CNS ) metastases may enrol : previously treat radiotherapy CNS disease , require chronic steroid therapy , compute tomography magnetic resonance imaging brain within 1 month study 's entry show stable disease neurological symptom ( exclude Grade 1 2 neuropathy ) . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 3 Potential subject measurable disease ( tumor mass least 1.5 cm ) document progressed MT3724_NHL_001_US Phase I/Ib study follow extend treatment possible new disease progression . Potential subject must least 9 day past last course MT3724 treatment recover side effect attribute MT3724 least Common Terminology Criteria Adverse Events ( CTCAE , v. 4.03 ; Appendix 4 ) Grade 2 prior initiate additional cycle MT3724 compassionate use protocol . Subjects preexist AEs screen severe life threaten CTCAE grade enrol . Laboratory requirement : Absolute neutrophil count ( ANC ) &gt; 1,000 per microliter ( μL ) Platelet count &gt; 25,000/μL ( The potential subject must asymptomatic thrombocytopenia must secondary bone marrow infiltration tumor secondary increase platelet consumption effect previous marrow suppress treatment infection . ) Hemoglobin ≥ 8.0 g/dL Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) ( unless due Gilbert 's Disease ) Aspartate aminotransferase ( AST ; SGOT ) alanine aminotransferase ( ALT ; SGPT ) &lt; 2.5 time ULN &lt; 5x ULN liver metastases present Serum creatinine ≤ 1.5 x ULN creatinine clearance ≥ 50 ml/min ( either measure estimate CockcroftGault formula ) . Females childbearing potential must negative serum urine pregnancy test within 3 day prior initiate dose . Male female subject reproductive potential must agree use appropriate contraceptive method study therapy 84 day follow last dose study medication . Patients comply protocol requirement include clinic visit intravenous infusion birth control measure may enrol . Female patient pregnant breast feed . Potential patient history another cancer basal cell carcinoma cervical intraepithelial neoplasia ( cervical cancer situ ) may enrol unless document previous cancer treat , disease free five year prior start study doctor 's judgment le 30 % risk relapse previous malignancy . Patients peripheral blood total lymphocyte count high 25,000/mm3 may enrol . Patients experience significant ( CTCAE Grade 3 4 without neutropenia ) infection within 2 week first dose MT3724 . Patients eligible use approved investigational antineoplastic therapy investigational therapy reason . Patients may receive systemic corticosteroid therapy prednisone dose &gt; 20 mg/day ( steroid equivalent ) within 2 week start study . Patients uncontrolled severe cardiovascular disease , include myocardial infarct unstable angina within 6 month prior start study treatment , New York Heart Association ( NYHA ) Class II great congestive heart failure , serious arrhythmia require medication treatment , clinically significant pericardial disease , cardiac amyloidosis may enrol . Patients known history drug abuse chronic neurologic , psychiatric , endocrine , metabolic , immunologic , hepatic renal disease ( include history hemolytic uremic syndrome ) opinion Investigator would adversely affect study participation . Patients know active Hepatitis C , HIV present history Hepatitis B Patients must receive vaccine 28 day prior administration first dose MT3724 receive vaccine study within 28 day last dose MT3724 . Patients suspect allergy sensitivity component MT3724 drug preparation base upon know allergy compound similar class anaphylactic severe infusion reaction human immunoglobulin monoclonal antibody administration n ot eligible . Patients allogeneic hematopoietic stem cell transplantation eligible . Patients major surgery within 6 week prior first dose study drug major surgery plan first 12 week MT3724 finish .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>CD20</keyword>
	<keyword>immunotoxin</keyword>
	<keyword>NHL</keyword>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>lymphoma</keyword>
	<keyword>cancer</keyword>
	<keyword>antibody</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>MT-3724</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
</DOC>